July 22, 2019
Ono Pharmaceutical and partner Bristol-Myers Squibb will collaborate with Bayer to develop a combination therapy pairing their PD-1 inhibitor Opdivo (nivolumab) and the German firm’s kinase inhibitor Stivarga (regorafenib) for colorectal cancer. The three companies said on July 18 that...read more